Scholarlink

Purpose <p>The aim of this study was to generate quantitative extracellular pH maps of tumors using a combination of a pH-sensitive iron chelate-based contrast agent (IBCA) and a pH-insensitive IBCA for concentration measurement, which we termed ratiometric pH magnetic resonance imaging (RpH-MRI).</p> Methods <p>The pH-sensitive IBCA of ethylenediamine-trans-cyclohexane diamine tetraacetic acid (Fe-en-tCDTA) was synthesized, along with the pH-insensitive IBCAs of trans-cyclohexane diamine tetraacetic acid (Fe-tCDTA) and diethylenetriamine-N,N,N′,N″,N″-pentaacetic acid (Fe-DTPA). The pH-dependent T1 contrast effects of these chelates were compared in water and serum phantoms at 0.94&#xa0;T, 3&#xa0;T and 7&#xa0;T. For in vivo pH mapping of tumors at 7&#xa0;T, 4T1 breast cancer cells were inoculated subcutaneously into the flanks of the BALB/c mice. RpH-MRI was performed with two sequential intravenous applications: first a pH-insensitive IBCA, followed by the pH-sensitive IBCA at the same dose (0.25 or 0.5&#xa0;mmol/kg) with an interval of either 30 or 60&#xa0;min. Quantitative pH maps were generated by calculating T1, S<sub>0</sub>, and relative maximum enhancement maps of the two injections, together with pH-dependent T1-relaxivity parameters derived from in vitro measurements of the pH-sensitive IBCA and pH-insensitive control IBCA.</p> Results <p>The T1 relaxivity (r1) of Fe-en-tCDTA was highly pH dependent, being approximately 2.7 times higher at pH 5.5 than at neutral pH, whereas Fe-DTPA and Fe-tCDTA showed stable r1 values between pH 5.5–7.4. In vivo, the time to maximum signal intensity (TMI) of the tumors of Fe-DTPA as control was comparable to that of Fe-en-tCDTA (2.57 ± 1.34&#xa0;min vs. 2.683 ± 0.89&#xa0;min, <i>p</i> = 0.7596, paired t test, 4 mice, 7 tumors) as well as for Fe-tCDTA as control versus Fe-en-tCDTA (3.30 ± 1.17&#xa0;min vs. 3.627 ± 1.12&#xa0;min, <i>p</i> = 0.2101, paired t test, 7 mice, 13 tumors), suggesting similar pharmacokinetics. The concentration distribution at TMI of the control chelates was assumed to be the same as that of the second injected Fe-en-tCDTA. The dynamic contrast enhanced MRI curve of the first injection of Fe-DTPA returned to baseline after 20–30&#xa0;min, whereas Fe-tCDTA took 30–60&#xa0;min to reach baseline. Calculated core and rim pH values were 6.512 ± 0.182 and 6.742 ± 0.121, respectively (<i>p</i> &lt; 0.0001, paired t test, 11 mice, 20 tumors) with core areas showing lower chelate concentrations but higher T1 relaxivity; the mean tumor-wide pH value was 6.632 ± 0.140.</p> Conclusion <p>Our results demonstrate the potential of high-resolution RpH-MRI based on pH-sensitive and pH-insensitive IBCAs for mapping tumor extracellular pH and concentration distribution.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

High-resolution quantitative mapping of extracellular pH by ratiometric MRI with iron chelates in a tumor mouse model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月20日

查看全文
  • Honglan Mi,
  • Philipp Boehm-Sturm,
  • Akvile Haeckel,
  • Ying Li,
  • Susanne Mueller,
  • Fei Ni,
  • Harald Kratz,
  • Marco Foddis,
  • Jing Xie,
  • Eyk Schellenberger

摘要

Purpose

The aim of this study was to generate quantitative extracellular pH maps of tumors using a combination of a pH-sensitive iron chelate-based contrast agent (IBCA) and a pH-insensitive IBCA for concentration measurement, which we termed ratiometric pH magnetic resonance imaging (RpH-MRI).

Methods

The pH-sensitive IBCA of ethylenediamine-trans-cyclohexane diamine tetraacetic acid (Fe-en-tCDTA) was synthesized, along with the pH-insensitive IBCAs of trans-cyclohexane diamine tetraacetic acid (Fe-tCDTA) and diethylenetriamine-N,N,N′,N″,N″-pentaacetic acid (Fe-DTPA). The pH-dependent T1 contrast effects of these chelates were compared in water and serum phantoms at 0.94 T, 3 T and 7 T. For in vivo pH mapping of tumors at 7 T, 4T1 breast cancer cells were inoculated subcutaneously into the flanks of the BALB/c mice. RpH-MRI was performed with two sequential intravenous applications: first a pH-insensitive IBCA, followed by the pH-sensitive IBCA at the same dose (0.25 or 0.5 mmol/kg) with an interval of either 30 or 60 min. Quantitative pH maps were generated by calculating T1, S0, and relative maximum enhancement maps of the two injections, together with pH-dependent T1-relaxivity parameters derived from in vitro measurements of the pH-sensitive IBCA and pH-insensitive control IBCA.

Results

The T1 relaxivity (r1) of Fe-en-tCDTA was highly pH dependent, being approximately 2.7 times higher at pH 5.5 than at neutral pH, whereas Fe-DTPA and Fe-tCDTA showed stable r1 values between pH 5.5–7.4. In vivo, the time to maximum signal intensity (TMI) of the tumors of Fe-DTPA as control was comparable to that of Fe-en-tCDTA (2.57 ± 1.34 min vs. 2.683 ± 0.89 min, p = 0.7596, paired t test, 4 mice, 7 tumors) as well as for Fe-tCDTA as control versus Fe-en-tCDTA (3.30 ± 1.17 min vs. 3.627 ± 1.12 min, p = 0.2101, paired t test, 7 mice, 13 tumors), suggesting similar pharmacokinetics. The concentration distribution at TMI of the control chelates was assumed to be the same as that of the second injected Fe-en-tCDTA. The dynamic contrast enhanced MRI curve of the first injection of Fe-DTPA returned to baseline after 20–30 min, whereas Fe-tCDTA took 30–60 min to reach baseline. Calculated core and rim pH values were 6.512 ± 0.182 and 6.742 ± 0.121, respectively (p < 0.0001, paired t test, 11 mice, 20 tumors) with core areas showing lower chelate concentrations but higher T1 relaxivity; the mean tumor-wide pH value was 6.632 ± 0.140.

Conclusion

Our results demonstrate the potential of high-resolution RpH-MRI based on pH-sensitive and pH-insensitive IBCAs for mapping tumor extracellular pH and concentration distribution.